MX2024002567A - Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. - Google Patents

Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas.

Info

Publication number
MX2024002567A
MX2024002567A MX2024002567A MX2024002567A MX2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A MX 2024002567 A MX2024002567 A MX 2024002567A
Authority
MX
Mexico
Prior art keywords
methods
protofibril antibody
disease
subject
subcutaneous formulations
Prior art date
Application number
MX2024002567A
Other languages
English (en)
Spanish (es)
Inventor
Pallavi Sachdev
Larisa Reyderman
Shobha Dhadda
Lynn Kramer
Ishani Landry
Chad Swanson
Akihiko Koyama
Michio KANEKIYO
Michael Irizarry
June Kaplow
David Verbel
Seiichi Hayato
Robert Gordon
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2024002567A publication Critical patent/MX2024002567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2024002567A 2021-08-30 2022-08-29 Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas. MX2024002567A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163260730P 2021-08-30 2021-08-30
US202263306050P 2022-02-02 2022-02-02
US202263269389P 2022-03-15 2022-03-15
US202263269463P 2022-03-16 2022-03-16
US202263364619P 2022-05-12 2022-05-12
PCT/US2022/041926 WO2023034230A1 (en) 2021-08-30 2022-08-29 Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2024002567A true MX2024002567A (es) 2024-03-20

Family

ID=83438517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002567A MX2024002567A (es) 2021-08-30 2022-08-29 Formulaciones subcutaneas de anticuerpo anti protofibrillas de beta-amiloide (abeta) y metodos de uso de las mismas.

Country Status (9)

Country Link
US (1) US20240352109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4395821A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532438A (cg-RX-API-DMAC7.html)
KR (1) KR20240053620A (cg-RX-API-DMAC7.html)
AU (1) AU2022338055A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230148A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024002567A (cg-RX-API-DMAC7.html)
TW (1) TW202328178A (cg-RX-API-DMAC7.html)
WO (1) WO2023034230A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL324807A (en) * 2023-06-09 2026-01-01 Eisai R&D Man Co Ltd Treatment methods using anti-Abeta protofibril antibody
CN116953261B (zh) * 2023-08-10 2024-09-17 浙江格物致知生物科技有限公司 一种检测脓毒症的联检试剂盒及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
SI2448968T1 (sl) 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
CN110655573B (zh) 2010-02-26 2023-07-18 生命北极神经科学公司 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
KR102630042B1 (ko) * 2016-10-27 2024-01-29 에자이 알앤드디 매니지먼트 가부시키가이샤 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물

Also Published As

Publication number Publication date
AU2022338055A1 (en) 2024-02-29
TW202328178A (zh) 2023-07-16
EP4395821A1 (en) 2024-07-10
JP2024532438A (ja) 2024-09-05
KR20240053620A (ko) 2024-04-24
WO2023034230A1 (en) 2023-03-09
CA3230148A1 (en) 2023-03-09
US20240352109A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
SG146666A1 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
ATE490470T1 (de) Therapieverfahren
MX2012002082A (es) Terapia de acetato de glatiramero de baja frecuencia.
CL2020000491A1 (es) Métodos para aumentar y/o estabilizar la función cardiaca en pacientes con enfermedad de fabry.
MX2022001287A (es) Composiciones y metodos de uso de celulas madre multipotentes para reducir la enfermedad y mejorar el bienestar.
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
WO2021222145A8 (en) Methods of treating agitation associated with alzheimer's disease
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
MX2023003258A (es) Tratamiento de enfermedades mediadas por nf-kb.
EP4523750A3 (en) Methods of reducing cerebrovascular events in patients with fabry disease
WO2022043273A3 (en) Oral care composition comprising a fructanase
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
MX2024005197A (es) Métodos para tratar la enfermedad de crohn con el anticuerpo específico anti-il23.
MX2024005374A (es) Metodos para tratar la enfermedad de celulas falciformes con voxelotor.
WO2022192639A3 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
WO2021034996A3 (en) Treatment of cardiovascular diseases
WO2021034616A8 (en) Methods of treating a subject with a cdc42-specific inhibitor
Patel et al. Bleomycin induced flagellate pigmentation
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
Strickler et al. Modern interpretation of mycotic infections of the feet and hands
EP4491231A3 (en) Regimen for treating a neisseria gonorrhoeae infection with gepotidacin
WO2007002571A3 (en) Use of an anti c5 complement antibody to treat patients with sickle cell disease
Nicholls et al. Special workshop on repeated and late reactions
RU119603U1 (ru) Аппарат для шинирования зубов при лечении заболеваний тканей пародонта